Overview
Globus Medical, Inc. is a medical technology company focused on products and healthcare solutions for musculoskeletal disorders. Its stated mission is “to improve the quality of life of patients with musculoskeletal disorders.” The company’s portfolio includes spinal and orthopedic implants, biologics and surgical instruments, alongside enabling technologies such as imaging, navigation, surgical planning and robotics.[1][2][3]
Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical serves markets worldwide, with operations across 65 countries. It reported more than 6,000 employees worldwide as of December 31, 2025, and FY2025 revenue of approximately $2.94 billion.[1][4][5][6] [1][2][3][4][5][6][5]
Products & services
Globus Medical’s products are organized into Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions include spinal implants and instruments, biologics, orthopedic products, spinal cord stimulation therapy, and neuromonitoring services. Spine products include fusion systems, intervertebral spacers, expandable implants, corpectomy devices, motion-preservation products, and treatments for vertebral compression fractures; biologics include allograft and synthetic materials.[7][8][9]
Orthopedic offerings include limb-reconstruction and fracture-fixation products such as plating systems, intramedullary nails, external fixation and compression screws, including the PRECiCE and ANTHEM platforms. The company also offers hip and knee arthroplasty implants, including primary and revision products. Its HFX SCS system delivers proprietary 10-kHz stimulation for chronic back and limb pain and painful diabetic neuropathy; the company describes the therapy as usable without paresthesia. Neuromonitoring combines software and nerve-avoidance algorithms with real-time feedback, and is offered through onsite and remote monitoring services.[10][11][12][13]
Enabling Technologies include imaging, navigation and robotics for surgical planning and implant placement. ExcelsiusGPS supports open and minimally invasive procedures, including screw and interbody-spacer placement; Excelsius3D provides intraoperative image-guided navigation, while ExcelsiusHub adds patient-array monitoring, tissue-sparing drills and registration options. ExcelsiusFlex supports robotic total knee arthroplasty, and ExcelsiusXR is a wearable extended-reality navigation headset. Surgimap provides patient-specific planning, deformity simulation and cloud-based imaging sharing.[14][15][16][17][18][19][20]
The company reports sales in the two broad categories of Musculoskeletal Solutions and Enabling Technologies; the reviewed materials do not provide product-level revenue percentages. First-quarter 2026 consolidated net sales were $759.854 million, compared with $598.121 million in first-quarter 2025.[7][21][22] [7][8][9][10][11][12][13][14][15][21][22][22][16][17][18][19][20][16][17][18][19][20]
Geographic presence
Globus Medical is headquartered in Audubon, Pennsylvania. Its U.S. footprint includes administrative, research, and training offices in Arizona, California, Colorado, Illinois, Maryland, New Jersey, North Carolina, and Texas, as well as manufacturing and fulfillment facilities in Massachusetts, Ohio, Pennsylvania, and Tennessee. The company identifies manufacturing or processing operations in Eagleville and Limerick, Pennsylvania; West Carrollton, Ohio; San Antonio, Texas; and Methuen, Massachusetts. It also manufactures spinal-cord-stimulation products at a facility in Costa Rica.[23][24][25]
Globus markets and sells products across North, Central and South America, Europe, Asia, Africa, and Australia, using direct sales personnel, independent representatives, and third-party distributors internationally. It reports leased distribution warehouses and administrative offices in 14 additional countries, without naming them in the cited disclosure.[23][24] For the six months ended June 30, 2026, sales were $1,223.993 million in the U.S. and $325.473 million internationally, out of $1,549.466 million total—approximately 79% U.S. and 21% international, calculated from reported amounts. The cited figures provide a U.S./international split, not country-level revenue.[26] [23][24][25][26][26][26][5]
Business segments
Globus Medical identifies two operating segments: **Musculoskeletal Solutions** and **Enabling Technologies**. It describes Musculoskeletal Solutions products across spinal implants, orthopedic trauma, hip and knee arthroplasty, regenerative biologics, advanced technology products, intraoperative neuromonitoring, and spinal cord stimulation services. Enabling Technologies includes the ExcelsiusGPS robotic guidance and navigation platform and Surgimap surgical-planning software; the company does not provide a detailed product-by-operating-segment allocation in its segment note.[27][28][15]
The company aggregates both operating segments into **one reportable segment**, citing factors including economic similarities and an integrated procedural-solutions approach. For FY2025, reported segment revenue was $2,938.931 million, representing 100% of revenue for the single reportable segment. Separate revenue contributions for Musculoskeletal Solutions and Enabling Technologies are not disclosed, so their individual percentages cannot be calculated from the reported data.[29][30] [27][28][15][29][30][5]
Company history
Globus Medical was founded in 2003 by David C. Paul. It completed its initial public offering in 2012, listing on the New York Stock Exchange as GMED.[31][32][33]
The company expanded into surgical robotics with its 2014 acquisition of Excelsius Surgical; its Excelsius GPS system received FDA clearance in 2017, the same year Paul transitioned from CEO to Executive Chairman and David M. Demski became CEO.[34][35][36] It acquired surgical-planning software company Nemaris in 2018.[15][37] In 2023, Globus completed its merger with NuVasive, which became a wholly owned subsidiary.[38][39] In 2025, it acquired Nevro, adding its chronic-pain stimulation business, and Keith Pfeil succeeded Daniel Scavilla as President and CEO.[40][41][42] In August 2026, Globus announced the acquisition of Higgs Boson Health to expand into AI-driven digital health solutions.[43] [31][15][38][40][41][32][33][34][35][36][37][39][42][43]
Sources
- GLOBUS MEDICAL INC — Full financial report (2025 Y)
- www.sec.gov[5]
- GLOBUS MEDICAL INC — Full financial report (2026 Q 2)
- GLOBUS MEDICAL INC — Full financial report (2026 Q 1)
- www.globusmedical.com[16]
- www.globusmedical.com[17]
- www.globusmedical.com[18]
- www.globusmedical.com[19]
- www.globusmedical.com[20]
- www.investors.globusmedical.com[32]
- www.sec.gov[33]
- www.investors.globusmedical.com[34]
- www.accessdata.fda.gov[35]
- www.investors.globusmedical.com[36]
- investors.globusmedical.com[37]
- www.investors.globusmedical.com[39]
- www.sec.gov[42]
- www.investors.globusmedical.com[43]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore GLOBUS MEDICAL INC in Finbar ↗